SEARCH

SEARCH BY CITATION

References

  • 1
    Moser M, Setaro J. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385392.
  • 2
    Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12:243249.
  • 3
    Van Wijk BLG, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:21012107.
  • 4
    Vollmer WM, Sacks FM, Ard J, et al, for the DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium trial. Ann Intern Med. 2001;135:10191028.
  • 5
    Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892896.
  • 6
    Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens. 2001;19:22712277.
  • 7
    Sinclair AM, Isles CG, Brown I, et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147:12891293.
  • 8
    Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982988.
  • 9
    Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352358.
  • 10
    Staessen JA, Thijs L, Fagard R, et al, for the Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539546.
  • 11
    Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama Study. Hypertension. 2005;45:240245.
  • 12
    Saseen JJ, Carter BL, Brown TER, et al. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28:109114.
  • 13
    Stergiou GS, Skeva II, Baibas NM, et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol. 2000;35:937941.
  • 14
    Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699705.
  • 15
    Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:22172226.
  • 16
    Grim CE. Low-renin “essential” hypertension: a variant of primary aldosteronism? Arch Intern Med. 1975;135:347350.
  • 17
    Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. BMJ. 1980;281:11011103.
  • 18
    Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333339.
  • 19
    Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925930.
  • 20
    Mahmud A, Mahgoub M, Hall M, et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18:16311635.
  • 21
    Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481487.
  • 22
    Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709716.
  • 23
    Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117123.
  • 24
    Weinberger MH, White WB, Ruilope L-M, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150:426433.